Impact of Respiratory Viral Infections in Infants With Cystic Fibrosis.

Clinical and Microbiological Impact of Respiratory Viral Infections in the Short and Medium Term in Infants (<24 Months) With Cystic Fibrosis.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02847156

Acronym

PREVIMUC

Enrollment

Registered

2016-07-28

Start date

2015-01-31

Completion date

2016-01-31

Last updated

2016-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis, Respiratory Viral Infection

Keywords

cystic fibrosis, viruses, respiratory viral infection, children

Brief summary

Respiratory Viral Infections (RVI) are particularly frequent in young children. Old data mention the deleterious role of some viruses such as the Respiratory Syncytial Virus in young children with cystic fibrosis (CF). However, recent epidemiological data on RVI in CF children are rare and the impact of most frequent viruses such as human rhinoviruses is usually not correctly evaluated. The aim of this study is to assess the frequency of lower and upper RVI during a 1 year follow-up in CF infants and to evaluate the impact of RVI at a clinical, microbiological and therapeutic level. Our hypothesis is that frequent and/or clinically severe RVIs have the worst impact in the short term and without any particular link with a specific virus as previously described.

Interventions

OTHERPhysical assessment

1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments

Study design

Allocation

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 24 Months

Healthy volunteers

Inclusion criteria

\- infant \<24 months with cystic fibrosis

Exclusion criteria

\- patient \>24 months

Design outcomes

Primary

Measure	Time frame
Number of Respiratory Viral Infection	up to 12 months

Secondary

Measure	Time frame	Description
Number of antibiotics treatments (oral or IV)	up to 12 months	—
Number of bronchodilator administrations	up to 12 months	—
Identification of respiratory viruses in throat-swabs	up to 12 months	A panel of 10 viruses will be tested using polymerase chain reaction (PCR) and RT-PCR technology.
Number of hospitalization or hospital admission due to upper or lower RVI	up to 12 months	—
Identification of bacterial flora in throat-swabs	up to 12 months	—
Number of corticosteroids administrations	up to 12 months	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026